021-51111890
购物车（）
sales@molnova.cn
ARV-825
CAS No. 1818885-28-7
ARV-825 ( ARV 825;ARV825 )
产品货号. M12800 CAS No. 1818885-28-7
ARV-825 is a hetero-bifunctional PROTAC (Proteolysis Targeting Chimera) that recruits BRD4 to the E3 ubiquitin ligase cereblon, leading to fast, efficient, and prolonged degradation of BRD4 via the proteasome.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥1191 | 有现货 |
|
| 10MG | ￥1442 | 有现货 |
|
| 25MG | ￥2252 | 有现货 |
|
| 50MG | ￥3013 | 有现货 |
|
| 100MG | ￥4504 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称ARV-825
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述ARV-825 is a hetero-bifunctional PROTAC (Proteolysis Targeting Chimera) that recruits BRD4 to the E3 ubiquitin ligase cereblon, leading to fast, efficient, and prolonged degradation of BRD4 via the proteasome.
-
产品描述ARV-825 is a hetero-bifunctional PROTAC (Proteolysis Targeting Chimera) that recruits BRD4 to the E3 ubiquitin ligase cereblon, leading to fast, efficient, and prolonged degradation of BRD4 via the proteasome; shows more significant and longer lasting c-MYC suppression than small molecule inhibitors (JQ1, OTX015); leads to a superior effect on BL cells proliferation suppression.Breast Cancer,Preclinical
-
同义词ARV 825;ARV825
-
通路Chromatin/Epigenetic
-
靶点Bromodomain
-
受体Bromodomain
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number1818885-28-7
-
分子量923.43
-
分子式C46H47ClN8O9S
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESO=C(NC1=CC=C(OCCOCCOCCOCCNC2=CC=CC(C(N3C(CC4)C(NC4=O)=O)=O)=C2C3=O)C=C1)C[C@H]5C6=NN=C(C)N6C7=C(C(C)=C(C)S7)C(C8=CC=C(Cl)C=C8)=N5
-
化学全称2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-(2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)ethoxy)phenyl)acetamide
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Lu J, et al. Chem Biol. 2015 Jun 18;22(6):755-63.
2. Abruzzese MP, et al. J Hematol Oncol. 2016 Dec 1;9(1):134.
3. Saenz DT, et al. Leukemia. 2017 Jan 31. doi: 10.1038/leu.2016.393.
2. Abruzzese MP, et al. J Hematol Oncol. 2016 Dec 1;9(1):134.
3. Saenz DT, et al. Leukemia. 2017 Jan 31. doi: 10.1038/leu.2016.393.
产品手册
关联产品
-
BRD-IN-17
BRD-IN-17 is a cell permeable, family VIII bromodomain tool compound with additional PB1(2) activity over and above that of PFI-3.
-
BAY-850
BAY-850 (BAY 850, BAY850) is a potent, isoform selective, cellularly active ATAD2 bromodomain inhibitor with binding IC50 of 166 nM in TR-FRET assay.
-
GNE-375
GNE-375 is a potent, selective BRD9 inhibitor with IC50 of 5 nM.
